Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 301–400 of 748
Nochowitz, B., Shapiro, N. L., Nutescu, E. A., & Cavallari, L. H. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l707 · Cited by 22
Outcomes of genetic testing in adults with a history of venous thromboembolism.
Segal, J. B., Brotman, D. J., Emadi, A., Necochea, A. J., Samal, L., Wilson, L. M., Crim, M. T., & Bass, E. B. (2009) · PubMed Central · Cited by 29
It's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism
Motsch, J., Walther, A., Böck, M., & Böttiger, B. W. (2006) · Current Opinion in Anaesthesiology · doi:10.1097/01.aco.0000192779.17151.65 · Cited by 22
Janoly-Duménil, A., Bourne, C., Loiseau, K., Luauté, J., Sancho, P. O., Ciancia, S., Caillet, F., Boisson, D., Rioufol, C., Plauchu, M. M., et al. (2011) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2011.02.007 · Cited by 22
Wijnen, P. A. H. M., Linssen, C. F. M., Haenen, G. R. M. M., Bekers, O., & Drent, M. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256350 · Cited by 24
“0 denotes an increased risk of bleeding.([2]) One of the bleeding complications occurring in patients receiving coumarins is diffuse alveolar hemorrhage (DAH).”
BackgroundMakar-Aušperger, K., Krželj, K., Benčić, M. L., Aumiler, M. R., Turk, V. E., & Božina, N. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000501 · Cited by 22
Prevention of Recurrent Idiopathic Venous Thromboembolism
Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000150641.65000.f2 · Cited by 22
Bromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
“This was followed by a 2003 study [37] that compared low-intensity warfarin therapy (INR goal 1.”
MethodBarillari, G., Londero, A. P., Brenner, B., Nauffal, D., Muñoz-Torrero, J. F. S., del Molino, F., Moustafa, F., Madridano, O., Martín‐Martos, F., Monréal, M., et al. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.02.013 · Cited by 22
Self-citationDuration of Anticoagulation After Cerebral Venous Sinus Thrombosis
Caprio, F., & Bernstein, R. A. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9661-1 · Cited by 23
Guidelines for the Diagnosis, Treatment, and Follow up of Pulmonary Embolism
Uresandi, F., Blanquer, J., Conget, F., de Gregorio, M. Á., Lobo, J. L., Otero, R., Rodríguez, E. P., Monréal, M., & Morales, P. (2004) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(06)60379-0 · Cited by 29
Can I Stop the Warfarin? A Review of the Risks and Benefits of Discontinuing Anticoagulation
Spiess, J. L. (2009) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.0164 · Cited by 20
Nguyen, G. C., & Sharma, S. A. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829c01ef · Cited by 24
Rodger, M. A., Miranda, S., Delluc, A., & Carrier, M. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.06.017 · Cited by 23
Self-citationAnticoagulants in the treatment of deep vein thrombosis
Merli, G. J. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.006 · Cited by 23
Hughes, D. A., & Pirmohamed, M. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725110-00001 · Cited by 20
Zeng, J., Yu, P., Cui, W., Wang, X., Ma, J., & Zeng, C. (2020) · Medicine · doi:10.1097/md.0000000000020782 · Cited by 20
Elfar, S., Elzeiny, S. M., Ismail, H., Makkeyah, Y., & Ibrahim, M. N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.847286 · Cited by 19
Wåhlander, K., Eriksson, H., Lundström, T., Clason, S. B., Wall, U., Nyström, P. O., Wessman, P., Schulman, S., & THRIVE III Investigators (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.05960.x · Cited by 19
“…gene G20210A mutation in the study population is consistent ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 133, 68–77 73 with those reported in other studies of patients with VTE (Kearon et al, 1999, 2003; Anderson & Spencer, 2003; Ridker et al, 2003; Bates & Ginsberg, 2004).”
BackgroundResultRollins, B. M., Silva, M. A., Donovan, J. L., & Kanaan, A. O. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.033 · Cited by 18
Weitz, J. I., & Chan, N. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679906 · Cited by 18
Self-citationThrombophilia Testing, Recurrent Thrombosis, and Women’s Health
Piazza, G. (2014) · Circulation · doi:10.1161/circulationaha.113.007664 · Cited by 19
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 40
Hensen, A. D. O., Lijfering, W. M., Cannegieter, S. C., Rosendaal, F. R., & Vlieg, A. V. H. (2019) · British Journal of Haematology · doi:10.1111/bjh.16075 · Cited by 18
Venous thrombosis: who should be screened for thrombophilia in 2014?
Kyrle, P. A. (2013) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.2083 · Cited by 18
Unanswered questions in venous thromboembolism
Weitz, J. I. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70135-5 · Cited by 19
“This question was addressed in two randomized clinical trials [21,22].”
BackgroundInfluentialSelf-citationBova, C., Bianco, A., Mascaro, V., & Nobile, C. G. A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.005 · Cited by 18
Extended Treatment of Venous Thromboembolism
Connors, J. M. (2013) · New England Journal of Medicine · doi:10.1056/nejme1215678 · Cited by 19
Streiff, M. B., Segal, J. B., Tamariz, L. J., Jenckes, M. W., Bolger, D. T., Eng, J., Krishnan, J. A., & Bass, E. B. (2006) · American Journal of Hematology · doi:10.1002/ajh.20691 · Cited by 17
Aykan, A. Ç., Gökdeniz, T., Kalçık, M., Astarcıoğlu, M. A., Gündüz, S., Karakoyun, S., Gürsoy, M. O., Oğuz, A. E., Ertürk, E., Çakal, B., et al. (2014) · Herz · doi:10.1007/s00059-013-4038-1 · Cited by 19
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.426 · Cited by 17
Self-citationDiagnosis and Management of Venous Thromboembolism
Minichiello, T., & Fogarty, P. F. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.12.001 · Cited by 17
“0) was tested in the extended treatment of unprovoked VTE in the PREVENT trial [77].”
MethodMoustafa, F., Roubin, J., Pereira, B., Barrès, A., Saint-Denis, J., Perrier, C., Mondet, M., Dutheil, F., & Schmidt, J. (2018) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-018-0515-0 · Cited by 21
Duration of Anticoagulation: Applying the Guidelines and Beyond
Bauer, K. A. (2010) · Hematology · doi:10.1182/asheducation-2010.1.210 · Cited by 18
Aspirin and recurrent venous thromboembolism
Prandoni, P., Noventa, F., & Milan, M. (2013) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355512475040 · Cited by 16
Legnani, C., Tosetto, A., Pengo, V., Ghirarduzzi, A., Testa, S., Prisco, D., Poli, D., Tripodi, A., Palareti, G., Cosmi, B., et al. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0759 · Cited by 17
Surveillance, anticoagulation, or filter in calf vein thrombosis
Yoon, D. Y., Riaz, A., Teter, K., Vavra, A. K., Kibbe, M. R., Pearce, W. H., Eskandari, M. K., Lewandowski, R. J., & Rodríguez, H. E. (2016) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2016.08.007 · Cited by 16
Recent advances in understanding, diagnosing and treating venous thrombosis
Chan, N., & Weitz, J. I. (2020) · F1000Research · doi:10.12688/f1000research.27115.1 · Cited by 18
Self-citationLong-Term Therapy of Venous Thromboembolism in Cancer Patients
Streiff, M. B. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0075 · Cited by 16
“, compliant, no risk factors for bleeding).(15) Patients with a second episode of VTE or a first episode associated with significant thrombophilic defects (e.”
BackgroundResultTalboom-Kamp, E. P. W. A., Verdijk, N. A., Kasteleyn, M. J., Harmans, L. M., Talboom, I. J. S. H., Numans, M. E., & Chavannes, N. H. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017909 · Cited by 19
Heit, J. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00014-2 · Cited by 19
Diagnosis, Prevalence, And Management Of Thromboembolism In Patients With Spinal Cord Injury
Green, D. (2003) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2003.11753701 · Cited by 17
Onundarson, P. T., Pálsson, R., Witt, D. M., & Guðmundsdóttir, B. R. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00327-1 · Cited by 17
Wang, Y., & Bajorek, B. V. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613506592 · Cited by 15
Nazha, B., Pandya, B., Spyropoulos, A. C., & Kessler, C. M. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1673690 · Cited by 16
Lutsey, P. L., Norby, F. L., Zakai, N. A., MacLehose, R. F., Chen, L. Y., Shah, S., Datta, Y. H., & Alonso, Á. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541445 · Cited by 16
Zhang, Z., Lei, J., Zhai, Z., Yang, Y., Wan, J., Xie, W., & Wang, C. (2019) · The Clinical Respiratory Journal · doi:10.1111/crj.12993 · Cited by 15
“either spontaneous or, if associated with an intervention, lasting for more than 24 hours; (4) spontaneous rectal bleeding (more than spotting on toilet paper); (5) gingival bleeding for more than 5 minutes; (6) bleeding leading to hospitalization and/or requiring surgical treatment; (7) bleeding leading to a transfus…”
BackgroundGage, B. F., Bass, A. R., Lin, H., Woller, S. C., Stevens, S. M., Al-Hammadi, N. J., Anderson, J. L., Li, J., Rodriguez, T., Miller, J. P., et al. (2019) · JAMA · doi:10.1001/jama.2019.12085 · Cited by 18
Changes in surrogate outcomes can be translated into clinical outcomes using a Monte Carlo model
van Walraven, C., Oake, N., Coyle, D., Taljaard, M., & Forster, A. J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.015 · Cited by 17
Hypercoagulability and venous thromboembolism: a review.
Mazza, J. J. (2004) · PubMed · Cited by 15
Retrievable vena cava filters: clinical experience
Dentali, F., Ageno, W., & Imberti, D. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mcp.0000239544.17208.5c · Cited by 15
Self-management of oral anticoagulation therapy--methodological and clinical aspects.
Christensen, T. D. (2011) · PubMed · Cited by 20
Wu, C. M., Dwivedi, D. J., Pepler, L., Lysov, Z., Waye, J. S., Julian, J. A., Desch, K. C., Ginsburg, D., Weitz, J. I., Kearon, C., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302137 · Cited by 16
Self-citationBenefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Prandoni, P., Lensing, A. W. A., Prins, M. H., Gebel, M., Pap, A. F., Homering, M., Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Cohen, A. T., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.009 · Cited by 14
Self-citationBurgazli, K. M., Bilgin, M., Kavukçu, E., Altay, M. M., Özkan, H. T., Coskun, U., Akdere, H., & Ertan, A. K. (2011) · Journal of the Turkish-German Gynecological Association · doi:10.5152/jtgga.2011.39 · Cited by 14
Roldan, T., Blanco, J. J. R., Villamañán, E., & Waxman, A. B. (2017) · Pulmonary Circulation · doi:10.1177/2045893217721903 · Cited by 14
Goldhaber, S. Z. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5576-7 · Cited by 14
“Among patients receiving low intensity anticoagulation, target INR between 1.5 and 1.9, the major bleeding rate was exactly the same as in the PREVENT Trial, 0.9 events per 100 person-years [7].”
BackgroundInfluentialThrombophilia screening: a matter of debate.
Kamphuisen, P. W., & Rosendaal, F. R. (2004) · PubMed · Cited by 14
Wakefield, T. W., Andrea, T., & Henke, P. K. (2014) · Circulation · doi:10.1161/circulationaha.114.012235 · Cited by 16
Schenker, C., Stalder, O., Méan, M., Tritschler, T., Righini, M., Rodondi, N., & Aujesky, D. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760365 · Cited by 14
Moutzouris, J. P., Chow, V., Chung, T., Curnow, J. L., Kritharides, L., & Ng, A. C. C. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0288 · Cited by 13
Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
Mansur, A. D. P., Takada, J. Y., Avakian, S. D., & Strunz, C. M. C. (2012) · Clinics · doi:10.6061/clinics/2012(06)01 · Cited by 13
Chen, W. T., White, C. M., Phung, O. J., Kluger, J., Ashaye, A. O., Sobieraj, D. M., Makanji, S. S., Tongbram, V., Baker, W. L., & Coleman, C. I. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0755 · Cited by 13
Rankin, J., Nagar, M., Crosby, J., Toomari, N., Pietras, R. J., & Ben-Zur, U. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-1135-9 · Cited by 13
Chronic Thromboembolic Pulmonary Hypertension: Medical Treatment
Özsu, S., & Çınarka, H. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.114761 · Cited by 13
Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics
Fox, K. A. A., White, H. D., Opie, J., Gersh, B. J., & Opie, L. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50014-9 · Cited by 13
Kearon, C. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0573-x · Cited by 13
“In a study that randomized patients with one or more episodes of unprovoked VTE to long-term anticoagulant therapy with either target INR 1.75 or target INR 2.5, standardintensity therapy reduced the risk of recurrence by twothirds compared to low-intensity therapy, and the rate of major bleeding was low, and similar…”
BackgroundResultInfluentialSelf-citationPrevention and Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Critically Ill Patients
Yang, J. C. (2005) · Critical Care Nursing Quarterly · doi:10.1097/00002727-200501000-00007 · Cited by 16
Liabeuf, S., Scaltieux, L.-M., Masmoudi, K., Roussel, B., Moragny, J., Andréjak, M., & Gras‐Champel, V. (2015) · Medicine · doi:10.1097/md.0000000000002366 · Cited by 13
Agrawal, V., & Kim, E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1111-2 · Cited by 15
Lau, A. Y. S., Tsafnat, G., Sintchenko, V., Magrabi, F., & Coiera, E. W. (2009) · Yearbook of Medical Informatics · doi:10.1055/s-0038-1638644 · Cited by 16
“The process of arriving at a patient-specific dosage is long and typically requires several adjustments and blood tests [55, 56].”
BackgroundGal, G. L., & Bounameaux, H. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00891.x · Cited by 13
Sevestre, M., Labarère, J., Brin, S., Carpentier, P., Constans, J., Degeilh, M., Deslandes, B., Elgrishi, I., Lanoye, P., Laroche, J.-P., et al. (2005) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(05)88206-x · Cited by 18
Ximelagatran: An Oral Direct Thrombin Inhibitor
Dager, W. E., Vondracek, T. G., McIntosh, B. A., & Nutescu, E. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e078 · Cited by 13
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Advances in the management of venous thromboembolism
Schulman, S. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.003 · Cited by 13
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 14
Burggraaf, J. L. I., van Rein, N., Klok, F. A., & Cannegieter, S. C. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16492 · Cited by 16
Braga, G. C., Brito, M. B., Ferriani, R. A., de Oliveira, L. C. O., Garcia, A. A., Pintão, M. C., & Vieira, C. S. (2013) · Contraception · doi:10.1016/j.contraception.2013.06.012 · Cited by 12
Bahbahani, H. M., AlTurki, A., Dawas, A., & Lipman, M. L. (2018) · BMC Nephrology · doi:10.1186/s12882-017-0809-x · Cited by 12
“The use of a target international normalized ratio (INR) between 2 and 3 decreases thromboembolic risks without a significant increase in the risk of major bleeding [1, 5, 6].”
BackgroundZhao, X., Zhou, L., Kou, Y., & Kou, J. (2022) · PubMed · Cited by 18
Tullett, J., Murray, E. T., Nichols, L., HOLDER, R. L., Lester, W., Rose, P. E., Hobbs, R. F., & Fitzmaurice, D. A. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-16 · Cited by 12
“Studies of extended treatment with low dose warfarin have confirmed that maximal benefit is conferred at standard therapeutic targets rather than fixed low dose regimes [11,12].”
BackgroundHarenberg, J., Jörg, I., & Weiß, C. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0076-9 · Cited by 12
Therapeutisches Vorgehen bei akuter Lungenembolie
Reiβig, A., & Kroegel, C. (2004) · Der Internist · doi:10.1007/s00108-004-1168-9 · Cited by 12
Antiphospholipid antibodies in critical illness
Dentali, F., & Crowther, M. A. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c9e363 · Cited by 11
Self-citationvan Geest‐Daalderop, J. H. H., Hutten, B. A., Péquériaux, N. C. V., Levi, M. M., & Sturk, A. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-008-0203-4 · Cited by 11
A new indication for statins to prevent venous thromboembolism? Not yet
Cushman, M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03282.x · Cited by 11
Kovacs, M. J. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00825.x · Cited by 11
Self-citationTreatment of Venous Thromboembolism
Merli, G. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.08.004 · Cited by 11
Pharmacogenetics of oral anticoagulants
Rojas, J. C., Aguilar, B., Rodrı́guez, E., & Collados, M. T. (2005) · Blood Coagulation & Fibrinolysis · doi:10.1097/01.mbc.0000174079.47248.0c · Cited by 11
Vrotniakaite-Bajerciene, K., Rütsche, S., Calzavarini, S., Quarroz, C., Stalder, O., Méan, M., Righini, M., Staub, D., Beer, J. H., Frauchiger, B., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186050 · Cited by 12
Venous thromboembolism: What to do after anticoagulation is started
Kaatz, S., Qureshi, W., & Lavender, R. C. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10175 · Cited by 12
Vedantham, S., Gloviczki, P., Carman, T. L., Lewis, S. Z., Schneider, P. A., Sabri, S. S., & Kolluri, R. (2023) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.123.012894 · Cited by 14
Couturaud, F., Pernod, G., Pison, C. M., Mismetti, P., Sanchez, O., Meyer, G., Parent, F., Girard, P., Simonneau, G., Drouet, L. O., et al. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)74358-4 · Cited by 10
Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing
Werner, D., Werner, U., Wuerfel, A., Grosch, A., Lestin, H., Eschenhagen, T., & Rau, T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0639-2 · Cited by 10
Giorgi‐Pierfranceschi, M., Micco, P. D., Cattabiani, C., Guida, A., Pagán, B., Morales, M. D. V., Salgado, E., Suriñach, J. M., Tolosa-Vilella, C., & Monréal, M. (2015) · Medicine · doi:10.1097/md.0000000000001915 · Cited by 10
Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study
Mazetto, B. D. M., Orsi, F. A., Silveira, S. A. F., Bittar, L. F., Flores-Nascimento, M. C., Zapponi, K. C. S., Colella, M. P., Paula, E. V. D., & Annichino‐Bizzacchi, J. M. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617700997 · Cited by 13
Imberti, D., Pomero, F., & Mastroiacovo, D. (2020) · Blood transfusion · doi:10.2450/2019.0265-18 · Cited by 12
Ripley, T. L., Havrda, D. E., Blevins, S. M., & Culkin, D. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.16.1638.50949 · Cited by 10
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.